Skip to main content
Figure 6 | Journal of Hematology & Oncology

Figure 6

From: Aloperine executes antitumor effects against multiple myeloma through dual apoptotic mechanisms

Figure 6

Aloperine suppresses human MM cell growth in vivo . (A) The mean ± SD of tumor volume (mm3) of each treatment group (n = 5/group) versus time (days). Mice were treated with PBS, TRAIL, aloperine, aloperine + TRAIL/bortezomib at the indicated doses for 30 days. (B) A significant delay in tumor growth was observed in the treated mice compared with PBS-treated control mice (a P < 0.001 versus PBS). Bars represent the mean ± SD. (C) Tumor lysates from control and drug-treated mice were subjected to Western blot analysis using anti-cFLIP, p-AKT, AKT, and p-PTEN antibodies; ALO, aloperine; Bor, bortezomib. (D) Mice were treated with the indicated drugs for 30 days, and blood samples were obtained to measure serum bilirubin, hemoglobin, and creatine levels using the Quantichrom Creatinine, Bilirubin, and Hemoglobin Assay kit (BioAssay Systems). Aloperine cured 5T33 multiple myeloma mice. 5T33 MM mice were treated with aloperine and bortezomib for 40–45 days. E: IgG2b expression in aloperine- and bortezomib-treated mice was measured using ELISA assays. a P < 0.001 versus PBS; b P < 0.001 versus bortezomib; c P < 0.05 versus TRAIL; d P < 0.05 versus aloperine. (F) Kaplan-Meier plots of mice treated with the indicated concentrations of PBS, aloperine, or bortezomib. Survival was significantly increased in aloperine- and bortezomib-treated mice compared with the untreated group (PBS). a P < 0.05 for the PBS group. a P < 0.001 versus the PBS group. Values represent the mean ± SD.

Back to article page